Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
复制标题
DOI：
10.1016/j.acra.2020.08.015
复制
发表时间：
2021-12
影响因子：
4.8
通讯作者：
Ross BD
中科院分区：
文献类型：
--
作者：
Hoff BA;Lemasson B;Chenevert TL;Luker GD;Tsien CI;Amouzandeh G;Johnson TD;Ross BD
胶质母细胞瘤图像评估采用MRI增强，t1加权和非对比t2加权FLAIR图像。疾病进展评估依赖于肿瘤直径的变化，而肿瘤直径的变化与生存率相关性较差。为了改善胶质母细胞瘤的治疗监测，我们研究了解剖排列FLAIR信号作为GBM进展的早期预测因子的连续体素比较。我们使用体素参数响应映射（PRM）分析了52名受试者的纵向归一化FLAIR图像（rFLAIR），以监测rFLAIR强度增加（PRMrFLAIR+）、减少（PRMrFLAIR -）或不变（PRMrFLAIR0）的体积分数。我们通过rFLAIR测定治疗前和治疗后10周的疗效。根据神经肿瘤学反应评估（RANO）标准定义的疾病稳定或部分反应的一部分受试者（N=26）的疾病进展风险在第10周至第20周期间通过PRMrFLAIR评估，并持续评估直到PRMrFLAIR+超过定义的阈值。将RANO定义的标准与prm衍生的肿瘤进展检测结果进行比较。在第10周，采用RANO标准（PFS: p<0.0001; OS: p<0.0001）、flair -高强度容积的相对变化（PFS: p=0.0011; OS: p<0.0001）和PRMrFLAIR+ (PFS: p<0.01; OS: p<0.001)对患者进行无进展生存期（PFS: PFS: p<0.01）和总生存期（OS）进行分层。PRMrFLAIR+还对应答患者在第10周至第20周之间的进展进行分层（PFS: p<0.05; OS: p=0.01），而flair容积测量的变化无法预测。作为连续评估，PRMrFLAIR+超过10%对患者在5.6个月后的无进展生存进行分层（p<0.0001），而RANO标准直到15.4个月才对患者进行分层（p<0.0001）。PRMrFLAIR可能提供胶质母细胞瘤疾病进展的早期生物标志物。
Glioblastoma image evaluation utilizes MRI contrast-enhanced, T1-weighted and non-contrast T2-weighted FLAIR acquisitions. Disease progression assessment relies on changes in tumor diameter, which correlate poorly with survival. To improve treatment monitoring in glioblastoma, we investigated serial voxel-wise comparison of anatomically-aligned FLAIR signal as an early predictor of GBM progression. We analyzed longitudinal normalized FLAIR images (rFLAIR) from 52 subjects using voxel-wise Parametric Response Mapping (PRM) to monitor volume fractions of increased (PRMrFLAIR+), decreased (PRMrFLAIR−), or unchanged (PRMrFLAIR0) rFLAIR intensity. We determined response by rFLAIR between pre-treatment and 10 weeks post-treatment. Risk of disease progression in a subset of subjects (N=26) with stable disease or partial response as defined by Response Assessment in Neuro-Oncology (RANO) criteria was assessed by PRMrFLAIR between weeks 10 and 20 and continuously until the PRMrFLAIR+ exceeded a defined threshold. RANO defined criteria were compared with PRM-derived outcomes for tumor progression detection. Patient stratification for progression-free survival (PFS) and overall survival (OS) was achieved at week 10 using RANO criteria (PFS: p<0.0001; OS: p<0.0001), relative change in FLAIR-hyperintense volume (PFS: p=0.0011; OS: p<0.0001), and PRMrFLAIR+ (PFS: p<0.01; OS: p<0.001). PRMrFLAIR+ also stratified responding patients’ progression between weeks 10 and 20 (PFS: p<0.05; OS: p=0.01) while changes in FLAIR-volume measurements were not predictive. As a continuous evaluation, PRMrFLAIR+ exceeding 10% stratified patients for progression-free survival after 5.6 months (p<0.0001), while RANO criteria did not stratify patients until 15.4 months (p<0.0001). PRMrFLAIR may provide an earlier biomarker of disease progression in glioblastoma.
登录
查看更多内容
影响因子：
1.9
作者：
Do, Richard Kinh;Reyngold, Marsha;Shukla-Dave, Amita
通讯作者：
Shukla-Dave, Amita
新诊断的胶质母细胞瘤对放化疗的单指数、扩散峰度和拉伸指数扩散 MR 成像反应。
影响因子：
3.9
作者：
Chakhoyan A;Woodworth DC;Harris RJ;Lai A;Nghiemphu PL;Liau LM;Pope WB;Cloughesy TF;Ellingson BM
通讯作者：
Ellingson BM
DOI：
10.1158/1078-0432.ccr-10-2098
发表时间：
2011-07-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Galbán CJ;Chenevert TL;Meyer CR;Tsien C;Lawrence TS;Hamstra DA;Junck L;Sundgren PC;Johnson TD;Galbán S;Sebolt-Leopold JS;Rehemtulla A;Ross BD
通讯作者：
Ross BD
影响因子：
5
作者：
Chang, Peter D.;Chow, Daniel S.;Lignelli, Angela
通讯作者：
Lignelli, Angela
DOI：
10.3174/ajnr.a4296
发表时间：
2015-04
期刊：
AJNR. American journal of neuroradiology
影响因子：
--
作者：
Baer AH;Hoff BA;Srinivasan A;Galbán CJ;Mukherji SK
通讯作者：
Mukherji SK